Microba Life Sciences
Logotype for Microba Life Sciences Limited

Microba Life Sciences (MAP) investor relations material

Microba Life Sciences Q2 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Microba Life Sciences Limited
Q2 2026 earnings summary29 Jan, 2026

Executive summary

  • Core clinical testing volumes grew 90% year-on-year, with an annualized run rate exceeding 21,300 and on track for over 24,000 core tests, supporting regional break-even in Australia and the UK for FY26.

  • Completed strategic transition from legacy products to high-margin core testing and Invivo-branded supplements, with legacy products fully discontinued and over AUD 1.6 million in legacy revenue replaced.

  • UK market adoption is outperforming Australia by 33% at the equivalent post-launch period, leveraging acquired customer base and enhanced product features.

  • AI-driven transformation improved operational efficiency, with 71.4% of customer inquiries resolved by AI agents and satisfaction scores above 90%.

  • Launched new product features and consolidated brands, reducing practitioner onboarding time and streamlining marketing.

Financial highlights

  • Core testing revenue up 123% year-on-year, with FY25 revenue at $15.67 million and core testing product revenue up 129% year-on-year.

  • Invivo supplement volume up 110% year-on-year, with UK supplement business delivering a record quarter and over 300 subscribers.

  • Net operating cash outflows reduced to $1.6m in Q2 FY26, reflecting cost reductions and R&D tax incentive receipt.

  • Cash balance as of 31 Dec 2025 was $11.27 million, with estimated 7 quarters of funding at current burn rate.

  • Cash receipts for the quarter were $3.6m, down 7% YoY due to timing of new 30-day payment terms.

Outlook and guidance

  • Targeting over 24,000 core test volumes for the full financial year, supporting regional break-even milestones in Australia and the UK.

  • Group EBITDA break-even expected with further scale and continued strong clinical adoption.

  • Expansion into the US and Europe planned, contingent on regulatory pathways and successful laboratory partnerships.

  • Cash receipts expected to normalize from Q3 FY26 as payment term changes cycle through.

  • Major product advancements and new Microbiome Explorer SKUs scheduled for launch in the UK.

What specific results will unlock therapeutic deals?
How does product-led growth reduce customer acquisition cost?
Detail non-dilutive funding opportunities
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Microba Life Sciences
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Microba Life Sciences Limited is a biotechnology company specializing in microbiome analysis and therapeutics. The company provides advanced gut microbiome testing services using metagenomic sequencing technology to offer insights into human health. Microba also conducts research and development to discover and develop microbiome-based therapeutics targeting conditions such as inflammatory and metabolic diseases. The company is headquartered in Brisbane, Australia, and its shares are listed on the ASX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage